Transcat Inc (TRNS)

NASD · Industrials · Specialty Business Services · USA

Transcat Inc is a small cap company (market value between $300 million and $2 billion) in the Specialty Business Services industry.

Transcat provides accredited calibration, maintenance, quality compliance, and validation services through its Service segment, along with asset management solutions for the life sciences industry. Through its Distribution segment, the company sells and rents test and measurement instruments globally. The company serves customers across highly regulated industries including pharmaceuticals, biotechnology, medical devices, aerospace and defense, and energy and utilities.

From its FY2026 annual report (Form 10-K)

Intrinsic value, DCF valuation, financial health and value investing analysis for the Transcat Inc stock.

Our verdict on TRNS

Overvalued: intrinsic value $42.32 per share, market price $99.65, margin of safety -135.5% (as of 2026-11-17).

Discounting its cash flows at 8.2% (average of 3 methods) values the shares at $42.32; the price of $99.65 is 135% above that value, and 79% of that value comes from beyond year five.

ETFs with the most weight in TRNS

17 more funds hold it; the full list is part of the paid plan.

More on TRNS

Browse

Peers in Specialty Business Services

All 42 Specialty Business Services stocks

Cheaper than TRNS in Specialty Business Services

14 more in this industry show a wider margin of safety.

Is TRNS undervalued or overvalued?

TRNS is overvalued (as of the 2026-11-17 close). Discounting its cash flows at 8.2% (average of 3 methods) values the shares at $42.32; the price of $99.65 is 135% above that value, and 79% of that value comes from beyond year five.

What is the intrinsic value of TRNS?

$42.32 per share (as of the 2026-11-17 close), against a market price of $99.65. That is a margin of safety of -135.5%. The value is the average of the 3 valuation methods that apply to this company, recomputed every night after the US close.